Cover Page

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Editorial Commentary 
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Jairo A. Zuluaga, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona
AME Clinical Trials Review  
2024;
2:
26  
(25 April 2024) 
PDF Full Text (119) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri
AME Clinical Trials Review  
2024;
2:
25  
(25 April 2024) 
PDF Full Text (63) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Immunotherapy unleashed: pioneering chemo-free neoadjuvant programmed cell death ligand 1 (PD-L1) inhibition for resectable non-small cell lung cancer (NSCLC)
Nikki E. Rossetti, Varun Puri
AME Clinical Trials Review  
2024;
2:
24  
(25 April 2024) 
PDF Full Text (64) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients
Akikazu Kawase
AME Clinical Trials Review  
2024;
2:
23  
(25 April 2024) 
PDF Full Text (57) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Confirmatory surgical exploration of the mediastinum after negative endobronchial ultrasound-guided transbronchial needle aspiration: which method and when to perform it, if needed
Mohamed Torky, Ramón Rami-Porta, José Sanz-Santos
AME Clinical Trials Review  
2024;
2:
22  
(25 April 2024) 
PDF Full Text (59) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma
Shinji Yuhara, Yoshihisa Shimada, Masaaki Sato
AME Clinical Trials Review  
2024;
2:
21  
(25 April 2024) 
PDF Full Text (63) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Chest tube after lung resection—a small change to a great benefit
Joao Santos Silva, Pierre-Emmanuel Falcoz
AME Clinical Trials Review  
2024;
2:
20  
(25 April 2024) 
PDF Full Text (62) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?
Charlotte De Bondt, Paul Van Schil
AME Clinical Trials Review  
2024;
2:
19  
(25 April 2024) 
PDF Full Text (78) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Genomic and molecular considerations for sotorasib treatment in KRAS G12C-mutant non-small cell lung cancer
Kevin Lu, Hatim Husain
AME Clinical Trials Review  
2024;
2:
18  
(25 April 2024) 
PDF Full Text (71) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
Lauren Tagliaferro Epler, Joel W. Neal
AME Clinical Trials Review  
2024;
2:
17  
(25 April 2024) 
PDF Full Text (55) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Breaking barriers: bridging the gap in lung cancer trials through inclusive representation
Julian A. Marin-Acevedo, Sonam Puri
AME Clinical Trials Review  
2024;
2:
16  
(25 April 2024) 
PDF Full Text (55) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Optimizing the role of immunotherapy in the management of resectable non-small cell lung cancer
Laercio DaSilva, Meredith J. McAdams, Arun Rajan
AME Clinical Trials Review  
2024;
2:
15  
(25 April 2024) 
PDF Full Text (63) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The ELUCIDATE trial: a step closer to complete resection of lung tumors
Arvindran Alaga, Masahide Oki
AME Clinical Trials Review  
2024;
2:
14  
(25 April 2024) 
PDF Full Text (59) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
Shuai Wang, Haiying Cheng
AME Clinical Trials Review  
2024;
2:
13  
(25 April 2024) 
PDF Full Text (54) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Combination metronomic chemotherapy and immunotherapy in non-small cell lung cancer remains exploratory: the VinMetAtezo trial
Fangdi Sun, Joel W. Neal
AME Clinical Trials Review  
2024;
2:
12  
(25 April 2024) 
PDF Full Text (58) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?
Noemi Maria Giorgiano, Francesca Pentimalli, Giovanni Natale, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli
AME Clinical Trials Review  
2024;
2:
11  
(25 April 2024) 
PDF Full Text (57) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Combining neoadjuvant and adjuvant immunotherapy breathes more life into the growing body of lung cancer treatment paradigms
Hailey A. Theeuwen, Anthony W. Kim
AME Clinical Trials Review  
2024;
2:
10  
(25 February 2024) 
PDF Full Text (156) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
Takahiro Karasaki
AME Clinical Trials Review  
2024;
2:
9  
(25 February 2024) 
PDF Full Text (180) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Commentary: is segmentectomy curative in patients with early-stage ground glass opacity predominant non-small cell lung cancer?
Abdulrahman Y. Hammad, Hiran C. Fernando
AME Clinical Trials Review  
2024;
2:
8  
(25 February 2024) 
PDF Full Text (95) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Changing the way we treat KRAS G12C non-small cell lung cancers
Marzia Del Re, Alessandro Russo, Christian Rolfo
AME Clinical Trials Review  
2024;
2:
7  
(25 February 2024) 
PDF Full Text (125) Peer Review File COI Form Open Access Get Permission
Currently no content available!

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>

Announcement more

Full implementation of transparent peer review at AME Clinical Trials Review (ACTR)

With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to fully implement ... More >>

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

I am excited to announce the launch of AME Clinical Trials Review (ACTR), an open-access, peer-reviewed journal publishing commentaries on clinical trials in all phases. More >>

Publishing Information

AME Clinical Trials Review is published by AME Publishing Company

AME Publishing Company